Evaluation of Frequency of Administration of Intravenous Bisphosphonate and Recurrent Skeletal-Related Events in Patients With Multiple Myeloma

Data from a retrospective cohort analysis of patients with newly diagnosed multiple myeloma receiving intravenous (IV) bisphosphonate therapy show that less frequent administration of IV bisphosphonate is associated with comparable recurrent skeletal-related event risk reductions versus more frequent administration.